OR 641
Alternative Names: OR-641Latest Information Update: 11 Dec 2023
At a glance
- Originator OncoResponse
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Leukocyte immunoglobulin-like receptor B1 inhibitors; LILRB2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Dec 2023 OR 641 is available for licensing as of 01 Dec 2023. https://oncoresponse.com/partnering/overview.php
- 01 Dec 2023 Preclinical trials in Solid tumours in USA (Parenteral) prior to November 2023 (OncoResponse pipeline, December 2023)
- 03 Nov 2023 Pharmacodynamics data from a preclinical study in Solid tumours released by OncoResponse